Emergent BioSolutions Receives EMA Agreement for Proposed Development Path of Investigational Chikungunya VLP Vaccine Candidate
GAITHERSBURG, Md. , Jan. 13, 2020 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced that it has received agreement from the European Medicines Agency (EMA) to pursue its...
Emergent BioSolutions Announces Preliminary 2019 Financial Results and Provides 2020 Financial Forecast
Full year 2019 preliminary revenues and adjusted profitability metrics in line with prior guidance Full year 2020 forecast reflects continued growth of core business as well as investments in key...
Emergent BioSolutions to Participate in Investor Conferences
GAITHERSBURG, Md. , Jan. 06, 2020 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the...
Emergent BioSolutions Board Members Dr. Sue Bailey and Dr. Kathryn C. Zoon Named Most Influential Corporate Directors
GAITHERSBURG, Md. , Dec. 20, 2019 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced that two members of its board of directors – Dr. Sue Bailey and Dr. Kathryn C. Zoon...
Emergent BioSolutions Presents Positive Immunogenicity Results From Phase 2 Study of Its Investigational Chikungunya VLP Vaccine Candidate
GAITHERSBURG, Md. , Nov. 22, 2019 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced updated results from the interim analysis of its Phase 2 clinical study evaluating the...
Emergent BioSolutions Announces Growth Strategy and 2024 Goals at Analyst and Investor Day
Company aspires to exceed $2 billion in revenue with 27%-30% adjusted EBITDA margin by year end 2024 GAITHERSBURG, Md. , Nov. 21, 2019 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS)...
Emergent BioSolutions to Host 2019 Analyst and Investor Day
GAITHERSBURG, Md. , Nov. 18, 2019 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) will be hosting an analyst and investor day on November 21, 2019 from 8:00 AM EST to 2:00 PM EST in...
Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2019
Q3 2019 performance above guidance Full year 2019 financial forecast reaffirmed GAITHERSBURG, Md. , Nov. 06, 2019 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) reported financial...
Emergent BioSolutions to Host 2019 Analyst & Investor Day
GAITHERSBURG, Md. , Oct. 21, 2019 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced that the company will host an analyst and investor day on November 21, 2019 in New...
Emergent BioSolutions Receives EMA Prime Designation for Its Chikungunya Virus VLP Vaccine Candidate
GAITHERSBURG, Md. , Oct. 10, 2019 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced that the company’s chikungunya virus (CHIKV) virus-like particle (VLP) vaccine...
Emergent BioSolutions to Release Third Quarter 2019 Financial Results and Conduct a Conference Call on November 6, 2019
GAITHERSBURG, Md. , Oct. 09, 2019 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, November 6, 2019 at 5:00 pm (Eastern Time) to discuss the...
Emergent BioSolutions Receives NIH Research Grant to Further Develop AP007, Its Development Stage Sustained-Release Nalmefene Treatment for Opioid Use Disorder
GAITHERSBURG, Md. , Sept. 27, 2019 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced a research grant awarded by the National Institute on Drug Abuse (NIDA), a component...